20 unchanged sentences
Our Insider Trading Policy permits our executive officers and directors to enter into trading plans designed to comply with Rule 10b5-1.
−Removed: During the three-month period ending December 31, 2024, we did not adopt or terminate any contract, instruction or written plan for the purchase or sale of our securities that are intended to satisfy the affirmative defense conditions
−Removed: of Rule 10b5–1(c) promulgated under the Securities Exchange Act of 1934, as amended or adopted or terminated a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).
−Removed: The following table describes contracts, instructions or written plans for the purchase or sale of our securities that are intended to satisfy the affirmative defense conditions of Rule 10b5–1(c) promulgated under the Securities Exchange Act of 1934, as amended (each a "Rule 10b5-1 Plan") adopted by our executive officers and directors during the three month period ending December 31, 2024:
−Removed: Date of Adoption
−Removed: Duration of Rule 10b5-1 Plan
−Removed: Aggregate Number of Securities to be Purchased Pursuant to the Rule 10b5-1 Plan
−Removed: Aggregate Number of Securities to be Sold Pursuant to the Rule 10b5-1 Plan
−Removed: Francis Leonard
−Removed: Executive Vice President, President Novocure Oncology
−Removed: November 5, 2024 December 24, 2024 - December 5, 2025
−Removed: During the three-month period ending December 31, 2024, none of our executive officers or directors terminated a Rule 10b5-1 trading plan or adopted or terminated a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).
+Added: During the three-month period ending December 31, 2025, neither we nor any of our executive officers or directors adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that are intended to satisfy the affirmative defense conditions of Rule 10b5–1(c) promulgated under the Securities Exchange Act of 1934, as amended or adopted or terminated a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).
DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
43 unchanged sentences
Number Exhibit Description Incorporated by Reference Filed
−Removed: Form Date Number
+Added: Number Exhibit Description Form Date Number Filed
4.5 Form of 0% Convertible Senior Note due 2025 (included in Exhibit 4.4)
3 unchanged sentences
8-K 11/9/20 10.1
−Removed: 10.2 L oan Agreement dated April 29.
+Added: 10.2 Loan Agreement dated April 29.
2024 among Novocure Luxembourg S.a.r.l., the subsidiary guarantors party thereto, BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP, and BioPharma Credit PLC, as collateral agent.**
36 unchanged sentences
Number Exhibit Description Incorporated by Reference Filed
−Removed: Form Date Number
+Added: Number Exhibit Description Form Date Number Filed
10.21 Form of Incentive Stock Option Agreement pursuant to the NovoCure Limited 2015 Omnibus Incentive Plan – Form of Performance Option Agreement for Israel #
10 unchanged sentences
10.26 Non-Employee Director Compensation Program
−Removed: 2/22/24 10.23
10.27 Employment Agreement, dated as of October 10, 2016, by and between NovoCure (Israel) Ltd.
31 unchanged sentences
Number Exhibit Description Incorporated by Reference Filed
−Removed: Form Date Number
+Added: Number Exhibit Description Form Date Number Filed
10.42 First Addendum dated June 9, 2020 to License and Collaboration Agreement, dated as of September 10, 2018, between NovoCure Limited and Zai Lab (Shanghai) Co., Ltd.
9 unchanged sentences
10.47 Employment Agreement, dated as of January 3, 2024, between Novocure USA LLC and Pritesh Shah#
−Removed: 10.48 E mploy ment Agreeme nt dated as of April 1 , 2022 b etween Novocure (Israel) Ltd.
−Removed: and Barak Ben-A rye#
−Removed: 10.49 Form s of Share Option Agreement under 202 4 Omnibus Incentive Plan #
−Removed: 10.50 F orm s of Rest ricted Share Unit Award Notice under 2024 Omnibus Incentive Plan #
−Removed: 10.51 F orm s of Performance-Based Restri cted Share Unit Awar d under 2024 O mnibus Incentive Plan #
+Added: 10.48 Employment Agreement dated as of April 1, 2022 between Novocure (Israel) Ltd.
+Added: and Barak Ben-Arye#
+Added: 2/27/25 10.48
+Added: 10.49 Forms of Share Option Agreement under 2024 Omnibus Incentive Plan#
+Added: 2/27/25 10.49
+Added: 10.50 Forms of Restricted Share Unit Award Notice under 2024 Omnibus Incentive Plan#
+Added: 2/27/25 10.50
+Added: 10.51 Forms of Performance-Based Restricted Share Unit Award under 2024 Omnibus Incentive Plan#
+Added: 2/27/25 10.51
+Added: 10.52 Separation and Release Agreement dated November 24, 2025, between Novocure GmbH and Ashley Cordova #
19 NovoCure Limited Policy Statement on Securities Trades by Company Officers, Directors and Employees
10 unchanged sentences
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document X
−Removed: 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document X
Number Exhibit Description Incorporated by Reference Filed
−Removed: Form Date Number
+Added: Number Exhibit Description Form Date Number Filed
+Added: 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document X
101.PRE Inline XBRL Extension Presentation Linkbase Document X
11 unchanged sentences
NovoCure Limited
−Removed: /s/ Ashley Cordova
−Removed: Ashley Cordova
+Added: /s/ Frank Leonard
+Added: Frank Leonard
Chief Executive Officer
1 unchanged sentence
Signature Title
−Removed: February 27, 2025 /s/ Ashley Cordova
+Added: February 26, 2026 /s/ Frank Leonard
Chief Executive Officer (Principal Executive Officer)
−Removed: Ashley Cordova
+Added: Frank Leonard
February 26, 2026 /s/ Christoph Brackmann
3 unchanged sentences
Doyle Executive Chairman and Director
−Removed: February 27, 2025 /s/ Asaf Danziger Director
+Added: February 26, 2026
+Added: /s/ Asaf Danziger Director
Asaf Danziger
3 unchanged sentences
Hung Director
−Removed: February 22, 2024 /s/ Kinyip Gabriel Leung Director
+Added: February 26, 2026
+Added: /s/ Kinyip Gabriel Leung Director
Kinyip Gabriel Leung
−Removed: February 22, 2024 /s/ Martin J.
+Added: February 26, 2026
+Added: /s/ Martin J.
Madden Director
1 unchanged sentence
Allyson Ocean
−Removed: February 22, 2024 /s/ Timothy J.
+Added: February 26, 2026
+Added: /s/ Timothy J.
Scannell Director
−Removed: February 22, 2024 /s/ Kristin Stafford Director
+Added: February 26, 2026
+Added: /s/ Kristin Stafford Director
Kristin Stafford
−Removed: February 22, 2024 /s/ William A.
+Added: February 26, 2026
+Added: /s/ William A.
Vernon Director
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.